Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.

Efficacy and safety of semaglutide versus placebo for people with schizophrenia on clozapine with obesity (COaST): a phase 2, multi-centre, participant and investigator- blinded, randomised controlled trial in Australia.

Open access

Abstract

BACKGROUND People with schizophrenia have a 16-20-year reduction in life expectancy, primarily due to cardiometabolic disease. Clozapine, the most efficacious antipsychotic for treatment-resistant schizophrenia, is associated with weight gain and metabolic dysfunction. Glucagon-like peptide-1 receptor agonists, including semaglutide, contribute to substantial weight loss in the general population, but their effect and safety profile in people with schizophrenia remain unknown. We evaluated the efficacy and safety of semaglutide for weight reduction in individuals with schizophrenia who were prescribed clozapine. METHODS COaST was an Australian randomised, placebo-controlled, multi-site trial, independent of pharmaceutical industry support, with methods informed by people with lived experience. Adults (aged 18-64 years) across six sites were randomly assigned (1:1) to once weekly subcutaneous semaglutide titrated to 2·0 mg or placebo for 36 weeks. Participants were included if they fulfilled criteria for schizophrenia or schizoaffective disorder, were prescribed clozapine for 18 weeks or more, had a BMI of at least 26 kg/m2, and had less than 5% bodyweight increase or loss in the previous 3 months. The primary outcome was percentage body weight change, analysed using a mixed model for repeated measures, at 36 weeks post-baseline assessment. All investigators and participants were masked to medication allocation. Secondary measures included clozapine and norclozapine concentrat…

Overview

Integrity signals

Registry

Crossref · 10.1016/s2215-0366(25)00129-4

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 41 references

Cited by

See all 62

Metadata

Authors
Siskind, D., Baker, A., Arnautovska, U., Warren, N., Russell, A., DeMonte, V., Halstead, S., Iyer, R., Korman, N., McKeon, G., Medland, S., Parker, S., Stedman, T., & Trott, M.
Affiliations
  • The University of Queensland (AU)
  • Queensland Centre for Mental Health Research (AU)
  • The Alfred Hospital (AU)
  • Metro South Health (AU)
  • Swinburne University of Technology (AU)
  • QIMR Berghofer Medical Research Institute (AU)
Corresponding author
Siskind, Dan
Venue
The Lancet Psychiatry
Publisher
Elsevier BV
Published
2025-07
Volume
12
Issue
7
Pages
493-503
ISSN
2215-0366 (ISSN-L)
OpenAlex
W4411166563
Cited by
62
References
41
Citations by year
2026: 46 · 2025: 16
FWCI
41.47
Type
journal article
Language
en
Open access
Locations
  • The Lancet Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • Griffith Research Online (submittedVersion, other-oa)
Funders
  • Metro South Health (2020\u2013070)
  • National Health and Medical Research Council (GNT 1194635)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
semaglutide, clozapine, schizophrenia, obesity, weight loss, GLP-1 receptor agonists, cardiometabolic risk, antipsychotic-induced weight gain, norclozapine, psychotic symptoms, treatment-resistant schizophrenia, drug safety, New Zealand, South Asia
MeSH terms
Semaglutide, Adolescent, Adult, Australia, Clozapine, Double-Blind Method, Glucagon-Like Peptides, Female, Humans, Male, Middle Aged, Obesity, Schizophrenia, Antipsychotic Agents, Weight Loss, Treatment Outcome, Glucagon-Like Peptide 1, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of semaglutide versus placebo for people with schizophrenia on clozapine with obesity (COaST): a phase 2, multi-centre, participant and investigator- blinded, randomised controlled trial in Australia. https://app.cochat.ai/papers/10.1016/s2215-0366(25)00129-4
The paper
Siskind, D., Baker, A., Arnautovska, U., Warren, N., Russell, A., DeMonte, V., Halstead, S., Iyer, R., Korman, N., McKeon, G., Medland, S., Parker, S., Stedman, T., & Trott, M. (2025). Efficacy and safety of semaglutide versus placebo for people with schizophrenia on clozapine with obesity (COaST): a phase 2, multi-centre, participant and investigator- blinded, randomised controlled trial in Australia. The Lancet Psychiatry. https://doi.org/10.1016/s2215-0366(25)00129-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.